Global Sodium Hyaluronate-based Products Market

Dublin, June 03, 2022 (GLOBE NEWSWIRE) -- The "Sodium Hyaluronate-based Products Market Share, Size, Trends, Industry Analysis Report, By Type; By Application; By Region; Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering. The global sodium hyaluronate-based products market size is expected to reach USD 16.79 billion by 2030 according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth. The key factors responsible for the industry growth include the rising prevalence of osteoarthritis and cataracts. For instance, according to the Centers for Disease Control and Prevention, the most frequent type of arthritis is osteoarthritis (OA). These alterations normally take time to manifest and worsen. Pain, stiffness, and edema are all symptoms of OA. Over 32.5 million adults in the United States suffer from OA. Further, as per the Government of India (GOI), osteoarthritis is one of the most common rheumatologic conditions, which normally affects joints, with a prevalence rate of around 22 to 39%, in India. Women are more likely than males to develop OA. Approximately 45 percent of women over 65 have symptoms, while 70% of those over 65 have radiographic evidence of OA. According to the World Health Organization (WHO), symptomatic osteoarthritis affects 9.6% of men and 18.0% of women over 60 worldwide. 80 percent of people with osteoarthritis have movement limitations, and 25% are unable to conduct their major daily activities. Based on the type, the injectable segment accounted for the largest revenue share in the industry in 2021. Due to a significant wide range of applications, such as dermal fillers in aesthetic procedures, pain treatment in osteoarthritis, surgical assistance in cataract extractions, and anti-adhesives in gynecological surgeries, the injectable type segment is growing. Industry players such as Anika Therapeutics Inc., Galderma SA, Cadila Pharmaceuticals Ltd., Fidia Farmaceutici S.p.A., Allergan, Inc., BohusBioTech AB, Ferring Pharmaceuticals B.V., Syner-Med (Pharmaceutical Products) Ltd., and LG Chem Ltd are some key players operating in the global industry. In July 2021, Coast Southwest announced the launch of EndiMoist. EndiMoist Hyaluronate-based is a high-purity sodium hyaluronate. EndiMoist offers a variety of Hyaluronate content in a variety of molecular weights to fulfill a variety of performances and usage needs. Enzymatic degradation produces EndiMoist MHA, a new generation of Oligo Hyaluronate. This novel technique has higher levels of safety and biological activity.

Key Topics Covered: 1. Introduction 2. Executive Summary 3. Research Methodology 4. Sodium Hyaluronate-based Products Market Insights 4.1. Sodium Hyaluronate-based Products Market - Industry Snapshot 4.2. Sodium Hyaluronate-based Products Market Dynamics 4.2.1. Drivers and Opportunities 4.2.1.1. Increase in the geriatric population 4.2.1.2. Growing awareness and a rising number of dermal filler procedures 4.2.2. Restraints and Challenges 4.2.2.1. High procurement costs 4.3. Porter's Five Forces Analysis 4.3.1. Bargaining Power of Suppliers (Moderate) 4.3.2. Threats of New Entrants: (Low) 4.3.3. Bargaining Power of Buyers (Moderate) 4.3.4. Threat of Substitute (Moderate) 4.3.5. Rivalry among existing firms (High) 4.4. PESTLE Analysis 4.5. Sodium Hyaluronate-based Products Industry trends 4.6. Value Chain Analysis 4.7. COVID-19 Impact Analysis 5. Global Sodium Hyaluronate-based Products Market, by Type 5.1. Key Findings 5.2. Introduction 5.2.1. Global Sodium Hyaluronate-based Products, by Type, 2018 - 2030 (USD Billion) 5.3. Topical 5.3.1. Global Sodium Hyaluronate-based Products Market, by Topical, by Region, 2018 - 2030 (USD Billion) 5.4. Injectable 5.4.1. Global Sodium Hyaluronate-based Products Market, by Injectable, by Region, 2018 - 2030 (USD Billion) 5.5. Others 5.5.1. Global Other Sodium Hyaluronate-based Products Market, by Procedures, by Region, 2018 - 2030 (USD Billion) 6. Global Sodium Hyaluronate-based Products Market, by Application 6.1. Key Findings 6.2. Introduction 6.2.1. Global Sodium Hyaluronate-based Products Market, by Application, 2018 - 2030 (USD Billion) 6.3. Pharmaceuticals 6.3.1. Global Sodium Hyaluronate-based Products Market, by Pharmaceuticals, by Region, 2018 - 2030 (USD Billion) 6.3.2. Opthalmology 6.3.2.1. Global Sodium Hyaluronate-based Products Market, by Opthalmology, by Region, 2018 - 2030 (USD Billion) 6.3.3. Orthopedic 6.3.3.1. Global Sodium Hyaluronate-based Products Market, by Orthopedic, by Region, 2018 - 2030 (USD Billion) 6.3.4. Urology 6.3.4.1. Global Sodium Hyaluronate-based Products Market, by Urology, by Region, 2018 - 2030 (USD Billion) 6.3.5. Others 6.3.5.1. Global Other Sodium Hyaluronate-based Products Market, by Region, 2018 - 2030 (USD Billion) 6.4. Cosmetics 6.4.1. Global Sodium Hyaluronate-based Products Market, by Cosmetics, by Region, 2018 - 2030 (USD Billion) 7. Global Sodium Hyaluronate-based Products Market, by Geography 8. Competitive Landscape 8.1. Expansion and Acquisition Analysis 8.1.1. Expansion 8.1.2. Acquisitions 8.2. Partnerships/Collaborations/Agreements/Exhibitions 9. Company Profiles 9.1. Allergan, Inc. 9.1.1. Company Overview 9.1.2. Financial Performance 9.1.3. Product Benchmarking 9.1.4. Recent Development 9.2. Anika Therapeutics Inc. 9.2.1. Company Overview 9.2.2. Financial Performance 9.2.3. Product Benchmarking 9.2.4. Recent Development 9.3. Bohus BioTech AB 9.3.1. Company Overview 9.3.2. Financial Performance 9.3.3. Product Benchmarking 9.3.4. Recent Development 9.4. Cadila Pharmaceuticals Ltd. 9.4.1. Company Overview 9.4.2. Financial Performance 9.4.3. Product Benchmarking 9.4.4. Recent Development 9.5. Ferring Pharmaceuticals B.V. 9.5.1. Company Overview 9.5.2. Financial Performance 9.5.3. Product Benchmarking 9.5.4. Recent Development 9.6. Fidia Farmaceutici S.p.A. 9.6.1. Company Overview 9.6.2. Financial Performance 9.6.3. Product Benchmarking 9.6.4. Recent Development 9.7. Galderma S.A. 9.7.1. Company Overview 9.7.2. Financial Performance 9.7.3. Product Benchmarking 9.7.4. Recent Development 9.8. L.G. Chem Ltd 9.8.1. Company Overview 9.8.2. Financial Performance 9.8.3. Product Benchmarking 9.8.4. Recent Development 9.9. Syner-Med (Pharmaceutical Products) Ltd 9.9.1. Company Overview 9.9.2. Financial Performance 9.9.3. Product Benchmarking 9.9.4. Recent Development

For more information about this report visit https://www.researchandmarkets.com/r/idwszd

Global Sodium Hyaluronate-based Products Market

These big names are down — but certainly not out.

The Dow Jones fell on strong jobs data. Tesla stock plunged on an Elon Musk move. Apple stock crumbled. Amazon fell after an executive quit.

In the world of stock legends, Ken Fisher stands out. The legendary investor founded his private financial advisory firm, Fisher Investments, in 1979, with just $250 in seed money. Today, Fisher’s company manages over $195 billion in total assets, and his personal net work exceeds $5 billion. Fisher has cast his eye on current market conditions. In recent published note, Fisher points out the obvious headwinds in the current environment: “Fear of the impact of the tragic, grinding war in Ukraine

Semiconductor specialist Nvidia (NASDAQ: NVDA) was down as much as 5.5%, iPhone maker Apple (NASDAQ: AAPL) was off by as much as 4.5%, and e-commerce kingpin Amazon (NASDAQ: AMZN) slipped as much as 3.5%. New warnings about the possibility of a recession sent a wide swath of stocks lower today, but there was also company-specific news for each of the technology stalwarts. Tesla CEO Elon Musk joined the chorus of business leaders sounding the alarm about the economy and the possibility of a recession.

Yahoo Finance auto reporter Pras Subramanian breaks down data from a new report indicating depressed U.S. auto sales amid rising inflation and interest rates.

It was a tough day for high-growth stocks, as a hot jobs number stoked inflation fears even as Elon Musk warned about the global economy.

Piper Sandler is scared of a computer memory glut, but Micron's stock price is cheap enough to already factor that in.

Don’t bail on stocks. Just choose them wisely.

Amazon stock is working on its sixth straight daily rally ahead of its 20-for-1 stock split. Here's what the charts say now.

One of the proposed shareholder measures, which was expected to be rubber-stamped by investors, has hit some surprising resistance.

The Dow Jones Industrial Average dropped after the jobs report. Tesla skidded after Musk said he had a "super bad feeling" about the economy.

It helped lead a rally in chip stocks, as Nvidia also did well, gaining 6.9%. AMD stock not only rotated over the prior month's high, it also held a key support level. What does that have to do with this week's breakout?

In this article, we will take a look at the 11 stocks in focus after releasing their earnings reports. You can skip our detailed analysis of these companies and go directly to the 5 Stocks in Focus After Releasing Their Earnings Reports. Recently, popular tech stocks, including Salesforce, Inc. (NYSE:CRM), NetApp, Inc. (NASDAQ:NTAP) and Pure […]

(Bloomberg) -- China has sentenced a former Communist Party city chief and securities regulator to death with a two-year reprieve for bribery and insider trading, state broadcaster CCTV reported.Most Read from BloombergOne-Third of Americans Making $250,000 Live Paycheck-to-Paycheck, Survey FindsTesla Pauses Hiring as Musk Aims for 10% Staff Cut, Reuters SaysElon Musk’s Ultimatum to Tesla Execs: Return to the Office or Get OutApple Plans to Make the iPad More Like a Laptop and Less Like a PhoneU

Brave investors are trying to buy S&P 500 stocks on the dip. But they're not even crazy enough to touch some.

See who joins Nvidia and GOOGL on this screen of Warren Buffett stocks based on the investing strategy of Berkshire Hathaway's CEO.

In this article, we take a look at 10 stocks that received bullish comments from Jim Cramer recently. You can skip the discussion on Jim Cramer’s history and investment philosophy and go directly go to Jim Cramer Loves These 5 Stocks. Jim Cramer is the man behind CNBC Investing Club and the host of CNBC […]

Turning Point Therapeutics snagged a $4.1 billion offer from Bristol Myers Squibb on Friday, and TPTX stock more than doubled.

We feel now is a pretty good time to analyse NIO Inc.'s ( NYSE:NIO ) business as it appears the company may be on the...

Exxon Mobil, PepsiCo, and JPMorgan Chase are among the biggest payers of dividends in absolute dollars, and they have solid yields to boot. Then there’s Apple and Microsoft.